Recital 20, Regulation (EU) 2024/1381

In forcesince 23 May 2024

To contribute to the completeness and high quality of the dossier and the smooth conduct of the joint clinical assessment, the health technology developer should be given the opportunity to request an assessment scope explanation meeting with the JCA Subgroup.